Rapid and specific detection of Mycoplasma pneumoniae using Pyrococcus furiosus argonaute combined with recombinase...

Area of Science:

• Microbiology
• Molecular Diagnostics
• Biotechnology

Background:

• Mycoplasma pneumoniae (MP) is a significant cause of human respiratory infections, including community-acquired pneumonia.
• Timely and accurate diagnosis of MP infection is essential for effective clinical management.
• Current diagnostic methods may have limitations in speed, accessibility, or cost.

Purpose of the Study:

• To develop and validate a novel, rapid molecular diagnostic assay for Mycoplasma pneumoniae.
• To combine recombinase polymerase amplification with Pyrococcus furiosus Argonaute protein (PfAgo) for MP detection.
• To assess the assay's specificity, sensitivity, and potential for use in diverse clinical settings.

Main Methods:

• Development of a diagnostic assay integrating recombinase polymerase amplification (RPA) with Pyrococcus furiosus Argonaute protein (PfAgo).
• Evaluation of assay specificity against common respiratory pathogens.
• Determination of the limit of detection (LOD).
• Validation using 37 clinical samples compared against quantitative real-time polymerase chain reaction (qPCR).

Main Results:

• The novel MP diagnostic assay exhibited high specificity, with no cross-reactivity observed.
• The limit of detection was determined to be 2 × 10^4 copies/μl.
• Clinical sample evaluation demonstrated 100% specificity and 86.36% sensitivity compared to qPCR.
• The complete workflow, including sample preparation, takes approximately 2.5 hours.

Conclusions:

• The RPA-PfAgo method offers a rapid, specific, and sensitive molecular diagnostic approach for Mycoplasma pneumoniae.
• The assay's requirement for basic instrumentation and short turnaround time makes it suitable for primary healthcare and resource-limited environments.
• This innovative diagnostic tool has the potential to improve early detection and management of MP infections globally.